Ash 2021 – Sanofi takes its time with fitusiran
Sanofi reckons it has a universal haemophilia therapy on its hands – but first it needs to test a lower dose.
Ash 2021 – the sun sets on Kymriah, but Novartis has a plan
Novartis unveils the first clinical backing for a two-day manufacturing technique that it hopes will recharge its Car-T efforts.
Ash 2021 – Bristol reveals its sons of Revlimid
Data in multiple myeloma and non-Hodgkin’s lymphoma make Bristol optimistic about follow-ons to Revlimid and Pomalyst.
Ash 2021 – Forma takes on a second Agios drug
Now in Servier’s hands, the Agios-discovered Tibsovo could soon face competition from Forma’s olutasidenib.
Ash 2021 – Global Blood stems the bleeding
The company reports decent data with its Oxbryta follow-on, but still has much to prove.
Ash 2021 – Sangamo and Sanofi enter the sickle cell gene editing fray
SAR445136 could take on Crispr and Vertex’s CTX001, but plenty of other groups have the same idea.
Ash 2021 – Bluebird looks to revive Lentiglobin
Data in sickle cell disease look encouraging, but a filing is a way away.
Ash 2021 – Precision moves quickly to deal with allo disappointment
Like its two competitors Precision shows lack of durability with its allogeneic Car-T approach, but makes a quick move to next-gen assets.
